Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCURO1382


A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Principal Investigator(s)

Sam Chang


  • Protocol No. VICCURO1382
  • Open Date: 02/10/2014
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: In phase 1, to determine the safety, toxicity, and preliminary efficacy profiles of intravesically administered nab-rapamycin at the maximum deliverable dose (MDD). In phase 2, to evaluate the utility (potential for clinical efficacy) and safety of nabrapamycin in the treatment of BCG refractory or recurrent nonmuscle invasive transitional cell carcinoma (TCC) of the bladder as measured by complete response rate (defined as negative bladder biopsy at 6 weeks post-treatment).
  • Disease Sites: Bladder
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Nab-rapamycin
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: Not Specified


None Provided.


Not provided. Please call for more information.